Navigation Links
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
Date:12/10/2007

oietin and thrombopoietin. Mutational activation of JAK2 is observed in the majority of patients with polycythemia vera, essential thrombocythemia and myelofibrosis, and is thought to drive the inappropriate expansion of blood cells observed in these conditions. Other members of the JAK family play critical roles in regulating immune responses, including the anti-viral and anti-parasitic responses.

XL019 is a potent JAK2 inhibitor (IC50 = 2 nM) with excellent selectivity versus the other members of the JAK kinase family (JAK1 IC50 = 130 nM, JAK3 IC50 = 250 nM, TYK2 IC50 = 340 nM). It is active against both wild type and mutationally activated forms of JAK2, and in preclinical studies showed good oral bioavailability and pharmacodynamic properties. Preclinical safety studies showed that XL019 was well tolerated.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential efficacy of XL019 and the timing of the initiation of pivotal trials for XL019. Words such
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... BEACH, California and AMSTERDAM, December 17 ,Agendia, ... today that,the US Food and Drug Administration (FDA) ... ages. MammaPrint is the only FDA-cleared,breast cancer recurrence ... three years, the FDA has issued four clearances ... , "This FDA clearance, ...
(Date:12/17/2009)... Suneva Medical, a privately-held aesthetic medical ... a multi-million dollar line of credit facility with ... credit facility will be used to fund commercial ... dermal filler on the market today, as well ... ,, "Today Suneva Medical entered into a multi-million ...
(Date:12/17/2009)... Corp. (OTC Bulletin Board: ISCR) a publicly-traded leading ... diagnostics and at home testing products for the ... of e-health technologies and revolutionary cell phone centric ... of the preparation of its Fiscal 2010 guidance, ... Directors and has rejected, as unneeded, multiple offers ...
Breaking Medicine Technology:FDA Broadens Clearance for Agendia's MammaPrint(R) 2Suneva Medical Signs Multi-Million Dollar Line of Credit Agreement with Western Technology Investment 2Suneva Medical Signs Multi-Million Dollar Line of Credit Agreement with Western Technology Investment 3Instacare Corp. Board of Directors Sets Growth Plans for 2010 2Precision Stability Storage Announces Upcoming Expansion 12665 1Precision Stability Storage Announces Upcoming Expansion 12665 2Precision Stability Storage Announces Upcoming Expansion 12665 3Dad Offers Personal Father 26apos 3Bs Day Message on Importance of Prostate Cancer Screenings 49157 1Dad Offers Personal Father 26apos 3Bs Day Message on Importance of Prostate Cancer Screenings 49157 2Dad Offers Personal Father 26apos 3Bs Day Message on Importance of Prostate Cancer Screenings 49157 3Allsup Medicare Advisor 28SM 29 Expands Service 3B Helps Seniors and People with Disabilities Make Best Medicare Choices 49155 1Allsup Medicare Advisor 28SM 29 Expands Service 3B Helps Seniors and People with Disabilities Make Best Medicare Choices 49155 2Allsup Medicare Advisor 28SM 29 Expands Service 3B Helps Seniors and People with Disabilities Make Best Medicare Choices 49155 3Allsup Medicare Advisor 28SM 29 Expands Service 3B Helps Seniors and People with Disabilities Make Best Medicare Choices 49155 4Allsup Medicare Advisor 28SM 29 Expands Service 3B Helps Seniors and People with Disabilities Make Best Medicare Choices 49155 5
... tcVisualize(TM) 3.0 with Monte Carlo brings predictability to whole ... of Phase ... Sept. 4 Tourtellotte Solutions, a,global leader in off-the-shelf ... consumer goods industries, today announced,the release of its tcVisualize(TM) ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that ... of ViroPharma, will present,at the Thomas Weisel Partners 2007 ... 2007. The conference is being held at the Four,Seasons ... present at the 14th Annual BioCentury Newsmakers,in the Biotech ...
Other Medicine Technology:Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator 2ViroPharma to Present at Three Upcoming Healthcare Conferences 2
(Date:12/17/2009)... 17, 2009 Racial and ethnic disparities in ... be detected early and treated successfully, including breast ... researchers at Columbia University,s Mailman School of Public ... at Columbia University Medical Center/NewYork-Presbyterian Hospital. Disparities ... more limited early detection and treatment options, such ...
(Date:12/17/2009)... someday ease accompanying lung infections , , THURSDAY, Dec. 17 ... infected with the swine flu virus, and researchers say ... key to the severity of the illness appears to ... the immune system fight off germs and disease. Researchers ... at 10 Spanish hospitals last summer found the highest ...
(Date:12/17/2009)... Program rewards eligible physicians meeting quality standards. Open to primary ... qualify for double-digit increases in reimbursement for commonly billed services, ... ... December 16, 2009 -- Blue Cross and Blue Shield ... reward health care quality in North Carolina by introducing a ...
(Date:12/17/2009)... Smith recently hired Deirdre Byrne to lead the firm’s Interim Leadership ... years of experience in healthcare consulting, Byrne will assume her duties ... ... (Vocus) December 17, 2009 -- B. E. Smith recently ... senior vice president. A seasoned executive with nearly 20 years of ...
(Date:12/17/2009)... Motionsoft, Inc. announced today that it has been ... Security Standards (DSS) certification, making it one of ... health and wellness space that has been granted ... result of a collaborative effort formed by the ... Worldwide, American Express, Discover Financial Services and JCB) ...
Breaking Medicine News(10 mins):Health News:Cancer survival disparities for most minority populations increase as cancers become more treatable 2Health News:BCBSNC Rewarding Physicians for Better Care, Not More Care, Through Blue Quality Physician Program, 2Health News:BCBSNC Rewarding Physicians for Better Care, Not More Care, Through Blue Quality Physician Program, 3Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3Health News:Motionsoft Completes PCI Compliance Certification 2
... juice with added vitamin A has the ability to reduce ... studies as// evidence. ,In the first study involving ... levels of chemical markers in the blood samples of people ... linked to a lower risk of liver disease, arteriosclerosis and ...
... was so fearful over his daughter Nicole's drastic weight loss that ... out the problem.// ,According to contactmusic.com, Richie was scared ... an eating disorder. ,He says: "Believe me, I've ... I went to her, and I said, 'Okay, what is it?' ...
... left the comforts of home to live in a dorm ... dad may be great, but dorm-life// also has its downfalls, ... picked up in communal bathrooms/showers. “Shared showers are one of ... wet, steamy atmosphere is a great place for them to ...
... cranberry juice have the ability to change E. coli ... of human illnesses, in ways that render them unable ... scientists at the Worcester Polytechnic Institute (WPI), Massachusetts, suggests ... E. coli bacteria that have become resistant to conventional ...
... over $100,000 from drug companies in unauthorized deals with the ... newspaper on Sunday. ,The actions of Dr. Thomas J. ... review, which concluded that he was guilty of "serious misconduct" ... the Los Angeles Times. ,The review found, "Dr. Walsh ...
People who have a low response to alcohol or the so called ability to...
Other Medicine News:Health News:Tips for Avoiding Foot Fungus in Communal Bathrooms 2Health News:Medical researcher Accused of 'serious misconduct' 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: